Real-world data showed reductions in healthcare resource utilization and improved glycemic control over 1 year with ...

Senseonics (NYSE:SENS) announced today that it received FDA clearance for its next-generation Eversense 365 CGM system.

Eversense 365 is a fully-implantable CGM with a 365-day sensor, making it the first 1-year CGM option for diabetes management ...

DUBLIN, Sept. 18, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today ...

addressing one of the major drawbacks of existing CGM devices, deemed invasive due to the requirement of a needle inserted ...

Let's not forget about Abbott Laboratories' impressive streak of 52 consecutive annual dividend increases, which also makes ...

The Continuous Glucose Monitoring Market is Growing at a CAGR of 7.80%, Driven by the Increasing Prevalence of Prediabetes ...

addressing one of the major drawbacks of existing CGM devices, deemed invasive due to the requirement of a needle inserted under the skin, which can cause discomfort. Additionally, a viscoelastic ...

If a patient receives a continuous glucose monitor device through their medical benefit, they may be more adherent and may ...

Continuous Glucose Monitoring (CGM) Systems Market The increasing incidence of diabetes and the detection of patient's blood glucose levels are raising the demand for continuous global monitoring ...

Patients living with diabetes who use continuous glucose monitoring devices had 35% lower total cost of care and 23% higher device adherence when therapy was provided through a medical vs. pharmacy be ...